Evotec's Academic Bridge LAB282 with Oxford University celebrating one year of impact

Evotec AG announced today that LAB282, the £ 13 m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-academic-bridge-lab282-with-oxford-university-celebrating-one-year-of-impact-5526

Weiterlesen

Ncardia and Evotec Entered a Licencing Agreement for Disease Modelling Using iPS Cells

Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/ncardia-and-evotec-entered-a-licencing-agreement-for-disease-modelling-using-ips-cells-5523

Weiterlesen

Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim

Evotec AG announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of EUR 2.00 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-clinical-milestone-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-5520

Weiterlesen

Carrick Therapeutics announces first patient dosed in phase 1 clinical trial of its oral CDK7 inhibitor: CT7001

Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, today announced that the first patient has been dosed in the phase 1 clinical programme of CT7001 Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-its-oral-cdk7-inhibitor-ct7001-5517

Weiterlesen

Evotec joins forces with academic leaders to accelerate drug discovery in kidney diseases and build "NEPLEX"

Evotec AG today announced a strategic collaboration on microfluidics technology including induced pluripotent stem cell („iPSC“) differentiation with leading academic institutions in the UK and Italy to accelerate the discovery of novel drugs to treat kidney diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-joins-forces-with-academic-leaders-to-accelerate-drug-discovery-in-kidney-diseases-and-build-neplex-5510

Weiterlesen

Evotec and Tesaro enter strategic partnership to discover novel immuno-oncology agents

Evotec AG and TESARO, Inc. today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-tesaro-enter-strategic-partnership-to-discover-novel-immuno-oncology-agents-3

Weiterlesen